The prevention of glutamate uptake inhibition by potential S1P2 antagonists currently under development could be beneficial in preventing glutamate neurotoxicity for a range of neurologic diseases with associated high brain levels of S1P. This evidence concerns the gene MBTPS1 and nervous system disorder.